sch 58261 Search Results


sch 58261  (Tocris)
95
Tocris sch 58261
Sch 58261, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sch+58261/pmc09407219__pnas__2208077119__sapp-105-0-6?v=Tocris
Average 95 stars, based on 1 article reviews
sch 58261 - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
ara2a antagonist sch58261  (Tocris)
95
Tocris ara2a antagonist sch58261
The effects of AMP, adenosine, selective ARs agonists or antagonists on wt- and CD73 -/- astrocytes. Wt- and CD73 -/- astrocytes were activated with LPS (100 ng/ml) plus IL-1β (10 ng/ml), with or without the addition of 5′-AMP (3 μM), adenosine (300 nM), selective ARA1 agonist/antagonist: CCPA (50 nM)/DPCPX (50 nM), selective <t>ARA2A</t> agonist/antagonist: CGS 21680 (259 nM)/SCH 58261 (100 nM), selective ARA2B agonist/antagonist: BAY 60-6538 (100 nM)/MRS 1754 (100 nM) and selective ARA3 agonist/antagonist: 2-Cl-IB-MECA (100 nM)/MRS1220 (5 μM). Culture medium was collected 2 days later, and RANTES and TNF-α levels in the supernatant were detected by ELISA. TNF-α (A) and Rantes (B) in the medium of activated CD73 -/- astrocytes treated with adenosine(Ado) and ARs antagonists or ARs agonists (C) . (D) TNF-α and Rantes in the medium of activated Wt-astrocytes treated with AMP, CD73 inhibitor and ARA1 antagonist. ∗∗ Indicates statistically significant differences ( p < 0.01). ns: no significance.
Ara2a Antagonist Sch58261, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sch+58261/pmc06549520-30-5-21?v=Tocris
Average 95 stars, based on 1 article reviews
ara2a antagonist sch58261 - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
sch58261  (Santa Cruz Biotechnology)
90
Santa Cruz Biotechnology sch58261
The effects of AMP, adenosine, selective ARs agonists or antagonists on wt- and CD73 -/- astrocytes. Wt- and CD73 -/- astrocytes were activated with LPS (100 ng/ml) plus IL-1β (10 ng/ml), with or without the addition of 5′-AMP (3 μM), adenosine (300 nM), selective ARA1 agonist/antagonist: CCPA (50 nM)/DPCPX (50 nM), selective <t>ARA2A</t> agonist/antagonist: CGS 21680 (259 nM)/SCH 58261 (100 nM), selective ARA2B agonist/antagonist: BAY 60-6538 (100 nM)/MRS 1754 (100 nM) and selective ARA3 agonist/antagonist: 2-Cl-IB-MECA (100 nM)/MRS1220 (5 μM). Culture medium was collected 2 days later, and RANTES and TNF-α levels in the supernatant were detected by ELISA. TNF-α (A) and Rantes (B) in the medium of activated CD73 -/- astrocytes treated with adenosine(Ado) and ARs antagonists or ARs agonists (C) . (D) TNF-α and Rantes in the medium of activated Wt-astrocytes treated with AMP, CD73 inhibitor and ARA1 antagonist. ∗∗ Indicates statistically significant differences ( p < 0.01). ns: no significance.
Sch58261, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sch+58261/pm18522960-58-23-20?v=Santa+Cruz+Biotechnology
Average 90 stars, based on 1 article reviews
sch58261 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
3 h] sch58261  (Schering-Plough corporation)
90
Schering-Plough corporation 3 h] sch58261
The effects of AMP, adenosine, selective ARs agonists or antagonists on wt- and CD73 -/- astrocytes. Wt- and CD73 -/- astrocytes were activated with LPS (100 ng/ml) plus IL-1β (10 ng/ml), with or without the addition of 5′-AMP (3 μM), adenosine (300 nM), selective ARA1 agonist/antagonist: CCPA (50 nM)/DPCPX (50 nM), selective <t>ARA2A</t> agonist/antagonist: CGS 21680 (259 nM)/SCH 58261 (100 nM), selective ARA2B agonist/antagonist: BAY 60-6538 (100 nM)/MRS 1754 (100 nM) and selective ARA3 agonist/antagonist: 2-Cl-IB-MECA (100 nM)/MRS1220 (5 μM). Culture medium was collected 2 days later, and RANTES and TNF-α levels in the supernatant were detected by ELISA. TNF-α (A) and Rantes (B) in the medium of activated CD73 -/- astrocytes treated with adenosine(Ado) and ARs antagonists or ARs agonists (C) . (D) TNF-α and Rantes in the medium of activated Wt-astrocytes treated with AMP, CD73 inhibitor and ARA1 antagonist. ∗∗ Indicates statistically significant differences ( p < 0.01). ns: no significance.
3 H] Sch58261, supplied by Schering-Plough corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sch+58261/pmc04485143-215-41-48?v=Schering-Plough+corporation
Average 90 stars, based on 1 article reviews
3 h] sch58261 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
3h]5-amino-7(2-phenyethyl)2-(2-furyl(pyrazolo-[4,3-e]-1,2,4-triazolo[1,5c]pyrimidine [3h]-sch 58261)  (NEN Life Science)
90
NEN Life Science 3h]5-amino-7(2-phenyethyl)2-(2-furyl(pyrazolo-[4,3-e]-1,2,4-triazolo[1,5c]pyrimidine [3h]-sch 58261)
The effects of AMP, adenosine, selective ARs agonists or antagonists on wt- and CD73 -/- astrocytes. Wt- and CD73 -/- astrocytes were activated with LPS (100 ng/ml) plus IL-1β (10 ng/ml), with or without the addition of 5′-AMP (3 μM), adenosine (300 nM), selective ARA1 agonist/antagonist: CCPA (50 nM)/DPCPX (50 nM), selective <t>ARA2A</t> agonist/antagonist: CGS 21680 (259 nM)/SCH 58261 (100 nM), selective ARA2B agonist/antagonist: BAY 60-6538 (100 nM)/MRS 1754 (100 nM) and selective ARA3 agonist/antagonist: 2-Cl-IB-MECA (100 nM)/MRS1220 (5 μM). Culture medium was collected 2 days later, and RANTES and TNF-α levels in the supernatant were detected by ELISA. TNF-α (A) and Rantes (B) in the medium of activated CD73 -/- astrocytes treated with adenosine(Ado) and ARs antagonists or ARs agonists (C) . (D) TNF-α and Rantes in the medium of activated Wt-astrocytes treated with AMP, CD73 inhibitor and ARA1 antagonist. ∗∗ Indicates statistically significant differences ( p < 0.01). ns: no significance.
3h]5 Amino 7(2 Phenyethyl)2 (2 Furyl(pyrazolo [4,3 E] 1,2,4 Triazolo[1,5c]Pyrimidine [3h] Sch 58261), supplied by NEN Life Science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sch+58261/pm15232288-49-12-15?v=NEN+Life+Science
Average 90 stars, based on 1 article reviews
3h]5-amino-7(2-phenyethyl)2-(2-furyl(pyrazolo-[4,3-e]-1,2,4-triazolo[1,5c]pyrimidine [3h]-sch 58261) - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
sch 58261  (Verlag GmbH)
90
Verlag GmbH sch 58261
The effects of AMP, adenosine, selective ARs agonists or antagonists on wt- and CD73 -/- astrocytes. Wt- and CD73 -/- astrocytes were activated with LPS (100 ng/ml) plus IL-1β (10 ng/ml), with or without the addition of 5′-AMP (3 μM), adenosine (300 nM), selective ARA1 agonist/antagonist: CCPA (50 nM)/DPCPX (50 nM), selective <t>ARA2A</t> agonist/antagonist: CGS 21680 (259 nM)/SCH 58261 (100 nM), selective ARA2B agonist/antagonist: BAY 60-6538 (100 nM)/MRS 1754 (100 nM) and selective ARA3 agonist/antagonist: 2-Cl-IB-MECA (100 nM)/MRS1220 (5 μM). Culture medium was collected 2 days later, and RANTES and TNF-α levels in the supernatant were detected by ELISA. TNF-α (A) and Rantes (B) in the medium of activated CD73 -/- astrocytes treated with adenosine(Ado) and ARs antagonists or ARs agonists (C) . (D) TNF-α and Rantes in the medium of activated Wt-astrocytes treated with AMP, CD73 inhibitor and ARA1 antagonist. ∗∗ Indicates statistically significant differences ( p < 0.01). ns: no significance.
Sch 58261, supplied by Verlag GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sch+58261/pm11487203-25-0-7?v=Verlag+GmbH
Average 90 stars, based on 1 article reviews
sch 58261 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
sch-58261  (EVJ Ltd)
90
EVJ Ltd sch-58261
The effects of AMP, adenosine, selective ARs agonists or antagonists on wt- and CD73 -/- astrocytes. Wt- and CD73 -/- astrocytes were activated with LPS (100 ng/ml) plus IL-1β (10 ng/ml), with or without the addition of 5′-AMP (3 μM), adenosine (300 nM), selective ARA1 agonist/antagonist: CCPA (50 nM)/DPCPX (50 nM), selective <t>ARA2A</t> agonist/antagonist: CGS 21680 (259 nM)/SCH 58261 (100 nM), selective ARA2B agonist/antagonist: BAY 60-6538 (100 nM)/MRS 1754 (100 nM) and selective ARA3 agonist/antagonist: 2-Cl-IB-MECA (100 nM)/MRS1220 (5 μM). Culture medium was collected 2 days later, and RANTES and TNF-α levels in the supernatant were detected by ELISA. TNF-α (A) and Rantes (B) in the medium of activated CD73 -/- astrocytes treated with adenosine(Ado) and ARs antagonists or ARs agonists (C) . (D) TNF-α and Rantes in the medium of activated Wt-astrocytes treated with AMP, CD73 inhibitor and ARA1 antagonist. ∗∗ Indicates statistically significant differences ( p < 0.01). ns: no significance.
Sch 58261, supplied by EVJ Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sch+58261/pm21496101-140-13-36?v=EVJ+Ltd
Average 90 stars, based on 1 article reviews
sch-58261 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
sch 58261  (Biosynth Carbosynth)
N/A
Adenosine A2A receptor antagonist. Adenosine A2A receptor antagonist.
   Buy from Supplier
sch 58261  (TargetMol)
N/A
   Buy from Supplier
[³h]sch 58261  (Aladdin Scientific Corporation)
N/A
   Buy from Supplier
sch 58261  (MedChemExpress)
N/A
SCH 58261 is a potent, selective and competitive antagonist of adenosine A2A receptor with an IC50 of 15 nM, and displays 323-, 53- and 100-fold more selective for A2A receptor than A1, A2B, and A3
   Buy from Supplier
sch 58261  (Aladdin Scientific Corporation)
N/A
Product Describtion:SCH 58261 is a potent, selective and competitive antagonist of adenosine A2A receptor with an IC50 of 15 nM, and displays 323-, 53- and 100-fold more selective for A2A receptor than A1, A2B, and
   Buy from Supplier

Image Search Results


The effects of AMP, adenosine, selective ARs agonists or antagonists on wt- and CD73 -/- astrocytes. Wt- and CD73 -/- astrocytes were activated with LPS (100 ng/ml) plus IL-1β (10 ng/ml), with or without the addition of 5′-AMP (3 μM), adenosine (300 nM), selective ARA1 agonist/antagonist: CCPA (50 nM)/DPCPX (50 nM), selective ARA2A agonist/antagonist: CGS 21680 (259 nM)/SCH 58261 (100 nM), selective ARA2B agonist/antagonist: BAY 60-6538 (100 nM)/MRS 1754 (100 nM) and selective ARA3 agonist/antagonist: 2-Cl-IB-MECA (100 nM)/MRS1220 (5 μM). Culture medium was collected 2 days later, and RANTES and TNF-α levels in the supernatant were detected by ELISA. TNF-α (A) and Rantes (B) in the medium of activated CD73 -/- astrocytes treated with adenosine(Ado) and ARs antagonists or ARs agonists (C) . (D) TNF-α and Rantes in the medium of activated Wt-astrocytes treated with AMP, CD73 inhibitor and ARA1 antagonist. ∗∗ Indicates statistically significant differences ( p < 0.01). ns: no significance.

Journal: Frontiers in Cellular Neuroscience

Article Title: Pro-inflammatory Effect of Downregulated CD73 Expression in EAE Astrocytes

doi: 10.3389/fncel.2019.00233

Figure Lengend Snippet: The effects of AMP, adenosine, selective ARs agonists or antagonists on wt- and CD73 -/- astrocytes. Wt- and CD73 -/- astrocytes were activated with LPS (100 ng/ml) plus IL-1β (10 ng/ml), with or without the addition of 5′-AMP (3 μM), adenosine (300 nM), selective ARA1 agonist/antagonist: CCPA (50 nM)/DPCPX (50 nM), selective ARA2A agonist/antagonist: CGS 21680 (259 nM)/SCH 58261 (100 nM), selective ARA2B agonist/antagonist: BAY 60-6538 (100 nM)/MRS 1754 (100 nM) and selective ARA3 agonist/antagonist: 2-Cl-IB-MECA (100 nM)/MRS1220 (5 μM). Culture medium was collected 2 days later, and RANTES and TNF-α levels in the supernatant were detected by ELISA. TNF-α (A) and Rantes (B) in the medium of activated CD73 -/- astrocytes treated with adenosine(Ado) and ARs antagonists or ARs agonists (C) . (D) TNF-α and Rantes in the medium of activated Wt-astrocytes treated with AMP, CD73 inhibitor and ARA1 antagonist. ∗∗ Indicates statistically significant differences ( p < 0.01). ns: no significance.

Article Snippet: The ARA1 antagonist DPCPX, the ARA2A antagonist SCH58261, the ARA2B antagonist MRS1754, the ARA3 antagonist MRS1220, and 5′-AMP were purchased from Tocris (R&D, United States).

Techniques: Enzyme-linked Immunosorbent Assay